NCT04289285View on ClinicalTrials.gov

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

804

Participants

Timeline

Start Date

April 29, 2020

Primary Completion Date

February 9, 2022

Study Completion Date

February 9, 2022

Conditions
Hypercholesterolemia
Interventions
DRUG

IBI306 450mg SC Q4W

Subjects will receive IBI306 450mg every 4 weeks subcutaneously.

DRUG

Placebo SC Q4W

Subjects will receive placebo every 4 weeks subcutaneously.

DRUG

IBI306 600mg SC Q6W

Subjects will receive IBI306 600mg every 6 weeks subcutaneously.

OTHER

Placebo SC Q6W

Subjects will receive placebo every 6 weeks subcutaneously.

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04289285 - Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia | Biotech Hunter | Biotech Hunter